Latest News for: a1c

Edit

A1c Below ADA Target in Six Months: New Nourish Data Shows the Impact of Dietitian-Led ...

Business Wire 17 Nov 2026
NATIONAL HARBOR, Md.--(BUSINESS WIRE)--Nourish, the country's largest dietitian-led metabolic health ...
Edit

Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

PR Newswire 28 Oct 2026
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs ... At 80 weeks, retatrutide met the primary and all key secondary endpoints, delivering greater A1C reduction and substantially more weight loss than Ozempic.1,2.
Edit

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss ...

The Greeneville Sun 01 Oct 2026
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine ....
Edit

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise ...

Morgan Citizen 30 Sep 2026
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity ... .
Edit

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

PR Newswire 30 Sep 2026
Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg ... delivering substantial weight loss and A1C reduction ... Change in A1C from an avg.
Edit

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

PR Newswire 30 Sep 2026
Change in A1C frommean baseline of8.22% at 52 Weeks iii ... Percent of participants achieving A1C ≤6.5%iii, iv  ... iiiResults of A1C and body weight were based on efficacy estimand.3.
Edit

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide ...

Morgan Citizen 29 Sep 2026
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks ... .
Edit

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

PR Newswire 29 Sep 2026
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks ... Additionally, Foundayo lowered A1C by 0.3% more than oral semaglutide 25 mg (95% CI -0.6%, -0.1%).
Edit

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

PR Newswire 29 Sep 2026
Retatrutide reduced A1C by up to an average of 1.6%, with up to 40.0% reaching an A1C of <5.7% ... Beyond substantially reducing weight, retatrutide also helped participants better control their A1C ... Change in A1C from ... achieving A1C ... achieving A1C.
Edit

AAJC 091826 blood tests

The Atlanta Journal-Constitution 21 Sep 2026
The number on your lab results can offer a 3-month snapshot of your blood sugar ....
  • 1
×